IMNN Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

3.250

Open

3.110

VWAP

3.15

Vol

13.01K

Mkt Cap

10.58M

Low

3.090

Amount

40.98K

EV/EBITDA(TTM)

--

Total Shares

3.40M

EV

4.24M

EV/OCF(TTM)

--

P/S(TTM)

--

Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.

Show More

Events Timeline

(ET)

2026-02-05

08:20:00

Imunon Announces Strategic Reorganization to Reduce Operating Costs

2025-12-30 (ET)

2025-12-30

08:50:00

IMUNON Enters Agreement to Sell 1,939,114 Shares to Institutional Investor

2025-12-29 (ET)

2025-12-29

11:20:00

IMUNON CEO Looks Ahead to Key Milestones in 2026

2025-11-13 (ET)

2025-11-13

07:46:23

Imunon Anticipates Sufficient Funds to Support Operations Through Q1 2026

2025-11-13

07:46:08

Imunon Announces Q3 Earnings Per Share of $1.16 Compared to $3.76 from the Previous Year

2025-11-10 (ET)

2025-11-10

07:59:42

Imunon Highlights Advancements on IMNN-001 During R&D Day

2025-10-30 (ET)

2025-10-30

08:16:27

Imunon to Showcase Phase 3 OVATION 3 Trial Results for IMNN-001

2025-10-14 (ET)

2025-10-14

08:31:04

Imunon to Showcase Phase 3 OVATION Study of IMNN-001

2025-09-22 (ET)

2025-09-22

08:16:57

Imunon: Results from OVATION 2 Study Confirm Efficacy Advantages of IMNN-001

2025-09-19 (ET)

2025-09-19

08:09:04

Imunon to Showcase Translational Findings from Phase 2 OVATION 2 Trial of IMNN-001

News

Newsfilter

2025-12-30Newsfilter

IMUNON Secures $7 Million from Institutional Investor in Direct Stock Offering

Globenewswire

2025-12-29Globenewswire

IMUNON Advances OVATION3 Study, Aiming for Breakthrough Therapy

Newsfilter

2025-12-29Newsfilter

IMUNON Advances OVATION3 Study, Aiming for Breakthrough Therapy

NASDAQ.COM

2025-11-13NASDAQ.COM

Imunon (IMNN) Q3 2025 Earnings Conference Call Transcript

Newsfilter

2025-11-13Newsfilter

IMUNON Releases Financial Results for Q3 2025 and Offers Business Update

Newsfilter

2025-11-10Newsfilter

IMUNON's Public Webcast Showcases Resilience and Innovation in the Quest for the First Approved Ovarian Cancer Immunotherapy

1 Analyst Rating

Wall Street analysts forecast IMNN stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

12.00

Averages

12.00

High

12.00

Current: 0.000

Low

12.00

Averages

12.00

High

12.00

D. Boral Capital

Jason Kolbert

Buy

to

Hold

downgrade

AI Analysis

2025-05-19

Reason

D. Boral Capital

Jason Kolbert

Price Target

AI Analysis

2025-05-19

downgrade

Buy

to

Hold

Reason

D. Boral Capital analyst Jason Kolbert downgraded Imunon to Hold from Buy without a price target. The company announced "encouraging" six-month follow-up data from its Phase 1 COVID-19 vaccine study, but the update is immaterial to the investment thesis, which remains centered on Imunon's ovarian cancer program, the analyst tells investors in a research note. The firm says the "more pressing development" is the recently filed prospectus for potentially dilutive financing that could create a significant number of new shares. Given the scale of dilution and uncertainty around shareholder approval, D. Boral downgraded the stock.

Boral Capital

D. Boral

Buy

downgrade

$29 -> $17

2025-05-13

Reason

Boral Capital

D. Boral

Price Target

$29 -> $17

2025-05-13

downgrade

Buy

Reason

D. Boral Capital lowered the firm's price target on Imunon to $17 from $29 and keeps a Buy rating on the shares. The firm now anticipates a series of dilutive financings that are likely to exceed its prior expectations. Imunon has entered a pivotal new phase in its development with the initiation of the Phase 3 OVATION 3 trial evaluating IMNN-001, its lead DNA-based immunotherapy candidate, in newly diagnosed advanced ovarian cancer, the analyst tells investors in a research note. With only $2.9M in cash as of March 31, the company's "financial position remains precarious," contends D. Boral.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IMNN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Imunon Inc (IMNN.O) is -0.77, compared to its 5-year average forward P/E of -1.24. For a more detailed relative valuation and DCF analysis to assess Imunon Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-1.24

Current PE

-0.77

Overvalued PE

0.08

Undervalued PE

-2.57

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

31.86

Current PS

0.00

Overvalued PS

90.61

Undervalued PS

-26.89

Financials

AI Analysis

Annual

Quarterly

Whales Holding IMNN

Trading Trends

People Also Watch

Frequently Asked Questions

What is Imunon Inc (IMNN) stock price today?

The current price of IMNN is 3.11 USD — it has increased 0.65

What is Imunon Inc (IMNN)'s business?

Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.

What is the price predicton of IMNN Stock?

Wall Street analysts forecast IMNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMNN is12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Imunon Inc (IMNN)'s revenue for the last quarter?

Imunon Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is Imunon Inc (IMNN)'s earnings per share (EPS) for the last quarter?

Imunon Inc. EPS for the last quarter amounts to -1.01 USD, decreased -76.94

How many employees does Imunon Inc (IMNN). have?

Imunon Inc (IMNN) has 25 emplpoyees as of March 11 2026.

What is Imunon Inc (IMNN) market cap?

Today IMNN has the market capitalization of 10.58M USD.